What high-risk features for stage I NSCLC would lead you to consider adjuvant osimertinib?

Would visceral pleural invasion lead you to consider adjuvant osimertinib?

Answer from: Medical Oncologist at Community Practice

In patients with resected stage IB non-small cell lung cancer (NSCLC) harboring EGFR mutations, adjuvant osimertinib may be considered for care. There is some evolving data that there may be some benefit in the presence of other risk factors in stage I, including solid or micropapillary histologic c...

Comments

Medical Oncologist at NYU Winthrop Hospital
Excellent review.

Medical Oncologist at University of Pittsburgh Medical Center
Agree, I would add 4 cm as well. :)

Medical Oncologist at West Virginia University Cancer Institute
I would agree with tumor > 4 cm, and I would ad...

Please select the option that best describes you:

What high-risk features for stage I NSCLC would lead you to consider adjuvant osimertinib?

Related Questions